Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation
Clinical Pharmacokinetics · 2026
DOI: 10.1007/s40262-026-01660-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacokinetics, 2026. Verfasst von Arnau Torrent-Rodríguez und 15 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Service, Division of Medicines, Hospital Clínic de Barcelona, C/Villarroel 170, 08036, Barcelona, Spain. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Drug Monitoring, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Col·legi Oficial de Farmaceutics de Barcelona, Universitat de Barcelona.
Abstract (Originalsprache)
Oral tyrosine kinase inhibitors and poly (adenosine diphosphate-ribose) polymerase inhibitors are widely used across solid tumors and hematologic malignancies and are typically administered at fixed doses. However, substantial interindividual pharmacokinetic variability results in heterogeneous systemic exposure, potentially leading to underexposure with reduced antitumor efficacy or overexposure with preventable toxicity. Therapeutic drug monitoring and model-informed precision dosing have emerged as complementary strategies to individualize dosing and optimize the exposure-response balance in routine oncology practice. This narrative problem-oriented review evaluates the clinical applicability of therapeutic drug monitoring and model-informed precision dosing for selected oral targeted agents, including epidermal growth factor receptor, anaplastic lymphoma kinase, BCR-ABL, vascular endothelial growth factor receptor, mitogen-activated protein kinase kinase, and multi-kinase inhibitors, as well as poly(adenosine diphosphate-ribose) polymerase inhibitors. For each agent, we assessed the presence of clinically meaningful exposure-response or exposure-toxicity relationships, the availability of validated assays, and the existence of actionable concentration thresholds. We also integrated an updated therapeutic drug monitoring usefulness score to contextualize the strength of recommendation. High-level evidence, including prospective interventional studies, supports exposure-guided dosing for imatinib and sunitinib, demonstrating improved molecular or clinical outcomes when predefined trough concentration targets are achieved. For alectinib, cabozantinib, trametinib, and lenvatinib, consistent exposure-response or exposure-toxicity relationships and pragmatic concentration thresholds support selective implementation, although randomized validation remains limited. For agents such as osimertinib, brigatinib, olaparib, and niraparib, monitoring appears most clinically relevant in toxicity-driven scenarios rather than for efficacy optimization. In contrast, lorlatinib currently lacks a clearly defined therapeutic window, limiting routine applicability. Across drugs, steady-state trough concentration remains the default sampling strategy. Clinical scenarios warranting measurement include early or unexpected disease progression, recurrent or severe adverse events, suspected drug-drug interactions, altered absorption, organ dysfunction, or concerns regarding adherence. Model-informed precision dosing extends conventional monitoring by integrating patient-specific covariates with pharmacokinetic models to simulate individualized dosing regimens. In conclusion, therapeutic drug monitoring and model-informed precision dosing are ready for selective clinical adoption in a subset of oral targeted therapies. Future prospective trials integrating pharmacometric tools with patient-centered outcomes are required to refine exposure targets and expand evidence-based implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pharmacy Service, Division of Medicines, Hospital Clínic de Barcelona, C/Villarroel 170, 08036, Barcelona, Spain.
- Pharmacy Service, Division of Medicines, Hospital Clínic de Barcelona, C/Villarroel 170, 08036, Barcelona, Spain. cbastida@clinic.cat.
- Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Barcelona, Spain. cbastida@clinic.cat.
- Department of Pharmacokinetics and Pharmacochemistry, Cochin University Hospital, Paris, France.
- Faculty of Pharmacy, Inserm UMR-S1144, Université Paris Cité, Paris, France.
- Medical Oncology Department, Hospital Clinic de Barcelona, Barcelona, Spain.
ORCID-Profile: Arnau Torrent-Rodríguez, Carla Bastida, Esther Carcelero San Martín, Inés Monge Escartín, Aleix B Fabregat-Bolufer, Dolors Soy Muner
Förderung
- Col·legi Oficial de Farmaceutics de Barcelona
- Universitat de Barcelona
Zitieren
APA
Torrent-Rodríguez, A., Bastida, C., Martín, E. C. S., Escartín, I. M., Puszkiel, A., Blanchet, B., Laguna, J. C., Gorria, T., Montes, A., Macías, I., Alvárez, A., Arance, A., Moreno, F. A., Fabregat-Bolufer, A. B., Soler, E., & Muner, D. S. (2026). Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-026-01660-2
Vancouver
Torrent-Rodríguez A, Bastida C, Martín ECS, Escartín IM, Puszkiel A, Blanchet B, et al. Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation. Clinical Pharmacokinetics. 2026. doi:10.1007/s40262-026-01660-2
BibTeX
@article{TorrentRodrguez2026,
author = {Torrent-Rodríguez, Arnau and Bastida, Carla and Martín, Esther Carcelero San and Escartín, Inés Monge and Puszkiel, Alicja and Blanchet, Benoit and Laguna, Juan Carlos and Gorria, Teresa and Montes, Angela and Macías, Ismael and Alvárez, Alberto and Arance, Ana and Moreno, Francisco Aya and Fabregat-Bolufer, Aleix B and Soler, Eva and Muner, Dolors Soy},
title = {Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation},
journal = {Clinical Pharmacokinetics},
year = {2026},
doi = {10.1007/s40262-026-01660-2}
}
EUVIMED